BG105782A - Reverse hydroxamate inhibitors of matrix metalloproteinases - Google Patents

Reverse hydroxamate inhibitors of matrix metalloproteinases

Info

Publication number
BG105782A
BG105782A BG105782A BG10578201A BG105782A BG 105782 A BG105782 A BG 105782A BG 105782 A BG105782 A BG 105782A BG 10578201 A BG10578201 A BG 10578201A BG 105782 A BG105782 A BG 105782A
Authority
BG
Bulgaria
Prior art keywords
matrix metalloproteinases
hydroxamate inhibitors
reverse hydroxamate
inhibitors
matrix metalloproteinase
Prior art date
Application number
BG105782A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Curtin
Yujia Dai
Steven DAVIDSEN
Howard HEYMAN
James Holmes
Michael MICHAELIDES
Douglas STEINMAN
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG105782A publication Critical patent/BG105782A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG105782A 1999-01-27 2001-08-03 Reverse hydroxamate inhibitors of matrix metalloproteinases BG105782A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
PCT/US2000/002038 WO2000044739A1 (en) 1999-01-27 2000-01-27 Reverse hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
BG105782A true BG105782A (en) 2002-04-30

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105782A BG105782A (en) 1999-01-27 2001-08-03 Reverse hydroxamate inhibitors of matrix metalloproteinases

Country Status (28)

Country Link
US (1) US20020007060A1 (xx)
EP (1) EP1147101B1 (xx)
JP (1) JP4718686B2 (xx)
KR (1) KR100748010B1 (xx)
CN (1) CN1222519C (xx)
AR (1) AR029329A1 (xx)
AT (1) ATE228122T1 (xx)
AU (1) AU764383B2 (xx)
BG (1) BG105782A (xx)
BR (1) BR0007278A (xx)
CA (1) CA2358951C (xx)
CO (1) CO5150194A1 (xx)
CZ (1) CZ20012591A3 (xx)
DE (1) DE60000819T2 (xx)
DK (1) DK1147101T3 (xx)
ES (1) ES2187443T3 (xx)
HK (1) HK1043115A1 (xx)
HU (1) HUP0105477A2 (xx)
IL (1) IL143713A0 (xx)
NO (1) NO20013669L (xx)
NZ (1) NZ512372A (xx)
PL (1) PL349771A1 (xx)
PT (1) PT1147101E (xx)
SK (1) SK10582001A3 (xx)
TR (1) TR200102159T2 (xx)
TW (1) TWI225486B (xx)
WO (1) WO2000044739A1 (xx)
ZA (1) ZA200104979B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2003063762A2 (en) * 2001-01-12 2003-08-07 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
US7511144B2 (en) 2001-09-07 2009-03-31 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP2543368A1 (en) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2183905T3 (es) * 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.

Also Published As

Publication number Publication date
CN1339032A (zh) 2002-03-06
TR200102159T2 (tr) 2001-12-21
WO2000044739A1 (en) 2000-08-03
ES2187443T3 (es) 2003-06-16
PL349771A1 (en) 2002-09-09
ZA200104979B (en) 2002-09-18
HK1043115A1 (zh) 2002-09-06
KR100748010B1 (ko) 2007-08-09
DE60000819T2 (de) 2003-09-04
CO5150194A1 (es) 2002-04-29
KR20010101709A (ko) 2001-11-14
NZ512372A (en) 2003-01-31
AU2739100A (en) 2000-08-18
PT1147101E (pt) 2003-04-30
JP2002535398A (ja) 2002-10-22
AU764383B2 (en) 2003-08-14
TWI225486B (en) 2004-12-21
SK10582001A3 (sk) 2001-12-03
ATE228122T1 (de) 2002-12-15
CA2358951C (en) 2009-10-20
IL143713A0 (en) 2002-04-21
DK1147101T3 (da) 2003-03-10
NO20013669L (no) 2001-09-27
EP1147101B1 (en) 2002-11-20
US20020007060A1 (en) 2002-01-17
DE60000819D1 (de) 2003-01-02
CA2358951A1 (en) 2000-08-03
JP4718686B2 (ja) 2011-07-06
NO20013669D0 (no) 2001-07-26
AR029329A1 (es) 2003-06-25
HUP0105477A2 (hu) 2002-05-29
BR0007278A (pt) 2001-11-27
EP1147101A1 (en) 2001-10-24
CN1222519C (zh) 2005-10-12
CZ20012591A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
IL133369A0 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
IL141410A0 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
MX9804623A (es) Precursores inactivos de farmacos inhibidores de trombina.
CA2260337A1 (en) Therapeutic agents
AU5414000A (en) Compounds
BG104779A (en) Inhibitors of phospholipase enzymes
HK1039110A1 (zh) 以新穎的合成物及組分作為蛋白酶抑制劑
SE9602646D0 (sv) Pharmaceutically-useful compounds
AU2220702A (en) Serine protease inhibitors
GB9715030D0 (en) Metalloproteinase inhibitors
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
BG105782A (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
BG104575A (en) Matrix metalloprotease inhibitors
SE0001803D0 (sv) New compounds i
BG107003A (en) Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB2324091A (en) Metalloproteinase inhibitors
AU8039501A (en) New amidino derivatives and their use as thrombin inhibitors
MXPA05000517A (es) Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz.
DE60012208D1 (de) Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs
RS20050181A (xx) Novi benzonaftiridini